Send to

Choose Destination
Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116.

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Author information

Surgery Branch, National Cancer Institute, National Institutes of Health, CRC-Building 10, Room 3-3940, 10 Center Drive, Bethesda, MD 20892-1201, USA.


Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma. In a pilot trial combining cell transfer with a maximum lymphodepleting regimen, complete durable responses were seen in 40% of patients, with complete responses ongoing beyond 3 to 7 years. Current approaches to cell transfer therapy using autologous cells genetically engineered to express conventional or chimeric T-cell receptors have mediated cancer regression in patients with metastatic melanoma, synovial sarcoma, neuroblastoma and refractory lymphoma. Adoptive cell transfer immunotherapy is a rapidly developing new approach to the therapy of metastatic cancer in humans. This Review will emphasize the current available applications of cell transfer immunotherapy for patients with cancer.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center